

# Rajamannar Ramasubbu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5967095/publications.pdf>

Version: 2024-02-01

54  
papers

1,772  
citations

279798

23  
h-index

289244

40  
g-index

54  
all docs

54  
docs citations

54  
times ranked

2864  
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional outcomes with bright light in monotherapy and combined with fluoxetine in patients with major depressive disorder: Results from the LIFE-D trial. <i>Journal of Affective Disorders</i> , 2022, 297, 396-400.	4.1	1
2	High-resolution virtual brain modeling personalizes deep brain stimulation for treatment-resistant depression: Spatiotemporal response characteristics following stimulation of neural fiber pathways. <i>NeuroImage</i> , 2022, 249, 118848.	4.2	9
3	Treatment-resistant major depressive disorder: Canadian expert consensus on definition and assessment. <i>Depression and Anxiety</i> , 2021, 38, 456-467.	4.1	38
4	Recruitment Challenges for Studies of Deep Brain Stimulation for Treatment-Resistant Depression. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 765-775.	2.2	5
5	Personality changes with subcallosal cingulate deep brain stimulation in patients with treatment-resistant depression. <i>Journal of Psychiatry and Neuroscience</i> , 2021, 46, E490-E499.	2.4	4
6	Early post-treatment blood oxygenation level-dependent responses to emotion processing associated with clinical response to pharmacological treatment in major depressive disorder. <i>Brain and Behavior</i> , 2021, 11, e2287.	2.2	5
7	Long versus short pulse width subcallosal cingulate stimulation for treatment-resistant depression: a randomised, double-blind, crossover trial. <i>Lancet Psychiatry</i> , 2020, 7, 29-40.	7.4	58
8	Thalamocortical connectivity in electroconvulsive therapy for major depressive disorder. <i>Journal of Affective Disorders</i> , 2020, 264, 163-171.	4.1	15
9	Tract-based analysis of target engagement by subcallosal cingulate deep brain stimulation for treatment resistant depression. <i>Brain Stimulation</i> , 2020, 13, 1094-1101.	1.6	22
10	Metabolic activity in subcallosal cingulate predicts response to deep brain stimulation for depression. <i>Neuropsychopharmacology</i> , 2020, 45, 1681-1688.	5.4	35
11	Rostral anterior cingulate glutamate predicts response to subcallosal deep brain stimulation for resistant depression. <i>Journal of Affective Disorders</i> , 2020, 266, 90-94.	4.1	10
12	Intrinsic thalamocortical connectivity varies in the age of onset subtypes in major depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 75-82.	2.2	13
13	Automatic classification of major depression disorder using arterial spin labeling MRI perfusion measurements. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 486-493.	1.8	19
14	F166. Imaging Biomarkers of Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression. <i>Biological Psychiatry</i> , 2018, 83, S303.	1.3	2
15	The impact of age of onset on amygdala intrinsic connectivity in major depression. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 343-352.	2.2	16
16	Dosing of Electrical Parameters in Deep Brain Stimulation (DBS) for Intractable Depression: A Review of Clinical Studies. <i>Frontiers in Psychiatry</i> , 2018, 9, 302.	2.6	69
17	Appetitive Symptoms Differentially Predict Treatment Response to Fluoxetine, Light, and Placebo in Nonseasonal Major Depression. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	2.2	4
18	The 5-HTTLPR and BDNF polymorphisms moderate the association between uncinate fasciculus connectivity and antidepressants treatment response in major depression. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 135-147.	3.2	44

#	ARTICLE	IF	CITATIONS
19	Thalamocortical connectivity in major depressive disorder. <i>Journal of Affective Disorders</i> , 2017, 217, 125-131.	4.1	70
20	Learning stable and predictive network-based patterns of schizophrenia and its clinical symptoms. <i>NPJ Schizophrenia</i> , 2017, 3, 22.	3.6	33
21	Amygdala responses to quetiapine XR and citalopram treatment in major depression: the role of 5-HTTLPR/Lg polymorphisms. <i>Human Psychopharmacology</i> , 2016, 31, 144-155.	1.5	12
22	Accuracy of automated classification of major depressive disorder as a function of symptom severity. <i>NeuroImage: Clinical</i> , 2016, 12, 320-331.	2.7	52
23	White matter integrity in major depressive disorder: Implications of childhood trauma, 5-HTTLPR and BDNF polymorphisms. <i>Psychiatry Research - Neuroimaging</i> , 2016, 253, 15-25.	1.8	32
24	The influence of 5-HTTLPR and Val66Met polymorphisms on cortical thickness and volume in limbic and paralimbic regions in depression: a preliminary study. <i>BMC Psychiatry</i> , 2016, 16, 61.	2.6	43
25	A negative randomised sham-controlled trial of ventral capsule/ventral striatum stimulation in treatment-resistant depression: an unsuccessful trial or treatment?. <i>Evidence-Based Mental Health</i> , 2016, 19, 59-59.	4.5	0
26	Intrinsic Local Beta Oscillations in the Subgenual Cingulate Relate to Depressive Symptoms in Treatment-Resistant Depression. <i>Biological Psychiatry</i> , 2016, 80, e93-e94.	1.3	21
27	Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2016, 73, 56.	11.0	191
28	Brain-derived neurotrophic factor and subcallosal deep brain stimulation for refractory depression. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 135-138.	2.6	11
29	Reduced Intrinsic Connectivity of Amygdala in Adults with Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 2014, 5, 17.	2.6	140
30	A Preliminary Study of the Influence of Age of Onset and Childhood Trauma on Cortical Thickness in Major Depressive Disorder. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	26
31	Influence of age of onset on limbic and paralimbic structures in depression. <i>Psychiatry and Clinical Neurosciences</i> , 2014, 68, 812-820.	1.8	19
32	Age of onset and corpus callosal morphology in major depression. <i>Journal of Affective Disorders</i> , 2013, 150, 703-706.	4.1	23
33	SSRIs associated with increased risk of brain haemorrhage, but absolute risks low. <i>Evidence-Based Mental Health</i> , 2013, 16, 54-54.	4.5	0
34	Double-blind optimization of subcallosal cingulate deep brain stimulation for treatment-resistant depression: a pilot study. <i>Journal of Psychiatry and Neuroscience</i> , 2013, 38, 325-332.	2.4	78
35	Methylphenidate-mediated reduction in prefrontal hemodynamic responses to working memory task: a functional near-infrared spectroscopy study. <i>Human Psychopharmacology</i> , 2012, 27, 615-621.	1.5	20
36	The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: diagnostic, assessment, and treatment principles. <i>Annals of Clinical Psychiatry</i> , 2012, 24, 82-90.	0.6	43

#	ARTICLE	IF	CITATIONS
37	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. <i>Annals of Clinical Psychiatry</i> , 2012, 24, 91-109.	0.6	56
38	Therapy for prevention of post-stroke depression. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2177-2187.	1.8	27
39	Differential neural activity and connectivity for processing one's own face: A preliminary report. <i>Psychiatry Research - Neuroimaging</i> , 2011, 194, 130-140.	1.8	6
40	Access to newer medications. <i>Canadian Journal of Psychiatry</i> , 2011, 56, 1-8.	1.9	1
41	Extended Evaluation of Serotonin Transporter Gene Functional Polymorphisms in Subjects with Post-Stroke Depression. <i>Canadian Journal of Psychiatry</i> , 2008, 53, 197-201.	1.9	22
42	Alterations in Neural Structures as Risk Factors for Depression. , 2008, , 37-61.		0
43	Methylphenidate modulates activity within cognitive neural networks of patients with post-stroke major depression: A placebo-controlled fMRI study. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 1251.	2.2	14
44	Neural Representation of Maternal Face Processing: A Functional Magnetic Resonance Imaging Study. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 726-734.	1.9	15
45	Serotonin Transporter Gene Promoter Region Polymorphism Associated With Poststroke Major Depression. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2006, 18, 96-99.	1.8	56
46	SSRI Treatment-Associated Stroke: Causality Assessment in Two Cases. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1197-1201.	1.9	11
47	Antidepressant treatment-associated behavioural expression of hypomania: a case series. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2004, 28, 1201-1207.	4.8	10
48	Cerebrovascular Effects of Selective Serotonin Reuptake Inhibitors. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 1642-1653.	2.2	73
49	Lamotrigine Treatment for Post-Stroke Pathological Laughing and Crying. <i>Clinical Neuropharmacology</i> , 2003, 26, 233-235.	0.7	36
50	Effect of Depression on Stroke Morbidity and Mortality. <i>Canadian Journal of Psychiatry</i> , 2003, 48, 250-257.	1.9	78
51	Treatment of Resistant Depression by Adding Noradrenergic Agents to Lithium Augmentation of SSRIs. <i>Annals of Pharmacotherapy</i> , 2002, 36, 634-640.	1.9	13
52	Relationship between depression and cerebrovascular disease: conceptual issues. <i>Journal of Affective Disorders</i> , 2000, 57, 1-11.	4.1	48
53	Functional Impairment Associated With Acute Poststroke Depression. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1998, 10, 26-33.	1.8	105
54	Diminished Serotonin-Mediated Prolactin Responses in Nondepressed Stroke Patients Compared With Healthy Normal Subjects. <i>Stroke</i> , 1998, 29, 1293-1298.	2.0	18